Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Appointed director
|
|
MARIZYME, INC. (MRZM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
8-K/A
| Quarterly results |
| 07/12/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"ANNEX A NOTICE OF CONVERSION The undersigned hereby elects to convert principal under the 15% Original Issue Discount Unsecured Subordinated Convertible Promissory Notes, due __, 2024 , in the original principal amount of $_______ , issued by Marizyme, Inc., a Nevada corporation , into shares of common stock, par value $0.001 per share, of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, i...",
"MARIZYME, INC. Class e COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, Hexin Global Ltd., an entity , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to Fourteen Million Seven Hundred Five Thousand Eight Hundred Eighty-Seven fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class E Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warrant...",
"MARIZYME, INC. Class f COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, Hexin Global Ltd., an entity , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to Fourteen Million Seven Hundred Five Thousand Eight Hundred Eighty-Seven fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class F Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warrant...",
"11.3",
"Plan of Distribution",
"AMENDMENT TO REGISTRATION RIGHTS AGREEMENT" |
|
| 05/24/2023 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data|
Docs:
|
"MARIZYME, INC. Class E COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, Hexin Global Ltd., an entity , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to Seven Million Five Hundred Thousand fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class E Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warrant may be exercised prior to its expir...",
"MARIZYME, INC. Class F COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, Hexin Global Ltd., an entity , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to Three Million Seven Hundred Fifty Thousand fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class F Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warrant may be exercised prior to it..." |
|
| 05/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"ANNEX A NOTICE OF CONVERSION The undersigned hereby elects to convert principal under the 15% Original Issue Discount Unsecured Subordinated Convertible Promissory Notes, due __, 2024 , in the original principal amount of $_______ , issued by Marizyme, Inc., a Nevada corporation , into shares of common stock, par value $0.001 per share, of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, i...",
"MARIZYME, INC. Class E COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, Walleye Opportunities Master Fund Ltd, an entity , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to Nine Hundred Eighty Thousand Three Hundred Ninety-Two fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class E Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warra...",
"MARIZYME, INC. Class F COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, Walleye Opportunities Master Fund Ltd, an entity , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to Nine Hundred Eighty Thousand Three Hundred Ninety-Two fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class F Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warra...",
"PLACEMENT AGENT WARRANT",
"PLACEMENT AGENT WARRANT",
"PLACEMENT AGENT WARRANT",
"11.3",
"Plan of Distribution" |
|
| 05/10/2023 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 04/26/2023 |
8-K/A
| Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"MARIZYME, INC. UNSECURED SUBORDINATED PROMISSORY NOTE US $1,000,000 February 6, 2023 FOR VALUE RECEIVED, Marizyme, Inc., a Nevada corporation , promises to pay to Walleye Opportunities Master Fund Ltd , the principal sum of One Million Dollars in lawful money of the United States of America, without interest payable thereon. The principal amount hereof shall be paid in full to the Holder on the ninetieth day following the issuance of this Note . Capitalized terms used herein but not defined herein shall have the meaning ascribed to them in that certain Securities Purchase Agreement, dated of even date herewith , pursuant to which the Holder is acquiring this Unsecured Subordinated Promissory Note . The following is a statement of the rights of the Holder of this Note and the terms and con...",
"MARIZYME, INC. CLASS D COMMON STOCK PURCHASE WARRANT Warrant No.: 01 Initial Exercise Date: ________, 2023 Warrant Value: $2,500,000 THIS CLASS D COMMON STOCK PURCHASE WARRANT certifies that, for value received, Walleye Opportunities Master Fund Ltd or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Public Offering Date ) and on or prior to 5:00 p.m. on___________, 2028 but not thereafter, to subscribe for and purchase from Marizyme, Inc., a Nevada corporation , a number of shares of Common Stock that is equal to the quotient of the Warrant Value as set forth above divided by the Public Offering Price . The purchase price of one Warrant Share under this Warrant shall be equal to the Exe...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 6, 2023, between Marizyme, Inc., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser..." |
|
| 01/17/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 12/28/2022 |
8-K
| Quarterly results |
| 08/18/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/25/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/09/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT, dated as of February 8, 2022 , by and between David Barthel and Marizyme, Inc., a Nevada corporation . RECITALS A. The Company and Employee previously entered into that certain Executive Employment Agreement, dated October 31, 2021 . B. The parties hereto desire to amend the Employment Agreement as set forth herein. AGREEMENT NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties hereto, intending to be legally bound, hereby agree as follows: 1. DEFINITIONS . All capitalized words and phrases used herein without definition shall have the meanings ascribed to them in the Employment Agreement. 2. AMENDMENTS. 2.1 The third paragraph in the Employment Agreement is hereby amen..." |
|
| 01/05/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/27/2021 |
8-K
| Entered into consulting agreement, Appointed a new director|
Docs:
|
"Appointment of Agent and Unitholder Representative",
"Plan of Distribution",
"WIRE INSTRUCTIONS FORM OF CONVERSION NOTICE The undersigned hereby irrevocably elects to convert $ ________________ of the principal amount of the above Note No. ___ into shares of Common Stock of Marizyme, Inc. according to the conditions hereof, as of the date written below. Date of Conversion: Conversion Price: Number of shares of Common Stock beneficially owned or deemed beneficially owned by the Holder on the Conversion Date:",
"MARIZYME, INC. Class C COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, [_________], a [_________] , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to [_____________] fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class C Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warrant may be exercised prior to its expiration pursuant to Sect...",
"EXCHANGE AGREEMENT",
"Placement Agency Agreement between Marizyme, Inc. and Univest Securities, LLC",
"Warrant Agreement",
"MARIZYME ANNOUNCES THE CLOSING OF MY HEALTH LOGIC ACQUISITION ALONG WITH INITIAL FINANCING JUPITER, Fla., December 23, 2021 /PRNewswire/ — Marizyme Inc. , is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. , along with a concurrent financing. My Health Logic’ s “lab-on-chip” technology platform and patient-centric digital point-of-care device, MATLOC 1, further strengthens Marizyme’ s life science technology product pipeline. Marizyme is actively seeking FDA approval for both MATLOC1 and a second product, DuraGraft. My Health Logic’ s MATLOC and Lab-on-Chip Technology Platform The excitement over microfluidics, also known as lab-on-a-chip technology, lies in its potential for producing revolutionary, timely, accessib..." |
|
| 11/16/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/05/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 09/22/2021 |
8-K
| Quarterly results |
| 07/16/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/09/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/28/2021 |
8-K
| Quarterly results |
| 03/31/2021 |
8-K
| Quarterly results |
| 03/19/2021 |
8-K
| Quarterly results |
| 02/26/2021 |
8-K
| Quarterly results |
| 02/26/2021 |
8-K
| Quarterly results |
| 02/04/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
8-K
| Quarterly results |
| 01/29/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|